Q3 Earnings Alert! Plan early for this week’s stock reports with all key data in 1 placeSee list

Camurus AB (CAMX)

Stockholm
Currency in SEK
Disclaimer
655.00
+5.00(+0.77%)
Closed
CAMX Scorecard
Full Analysis
Impressive gross profit margins
Fair Value
Day's Range
633.00658.50
52 wk Range
312.80715.00
Bid/Ask
655.00 / 655.00
Prev. Close
650
Open
648
Day's Range
633-658.5
52 wk Range
312.8-715
Volume
52,312
Average Volume (3m)
72,084
1-Year Change
100.31%
Fair Value
Unlock
Fair Value Upside
Unlock
CAMX Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
756.00
Upside
+15.42%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple

Camurus AB Company Profile

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud’s phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; and Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity, as well as licensing agreement with Solasia Pharma. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden. The company operates as a subsidiary of Sandberg Development AB.

Employees
213
Market
Sweden

Compare CAMX to Peers and Sector

Metrics to compare
CAMX
Peers
Sector
Relationship
P/E Ratio
172.5x−5.6x−0.6x
PEG Ratio
−3.69−0.120.00
Price/Book
13.2x6.5x2.6x
Price / LTM Sales
24.2x15.8x3.2x
Upside (Analyst Target)
17.0%73.0%43.9%
Fair Value Upside
Unlock3.3%7.8%Unlock

FAQ

What Is the Camurus AB (CAMX) Stock Price Today?

The Camurus AB stock price today is 655.00.

What Stock Exchange Does Camurus AB Trade On?

Camurus AB is listed and trades on the Stockholm stock exchange.

What Is the Stock Symbol for Camurus AB?

The stock symbol for Camurus AB is "CAMX."

What Is the Camurus AB Market Cap?

As of today, Camurus AB market cap is 38.52B.

What is Camurus AB Earnings Per Share?

The Camurus AB EPS is 3.95.

What Is the Next Camurus AB Earnings Date?

Camurus AB will release its next earnings report on 11 Feb 2025.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.